Bipolar androgen therapy (BAT) for nonmetastatic castration-resistant prostate (nmCRPC) cancer progressing on darolutamide: Working Out M0 BAT (WOMBAT; ANZUP 2201).
Year: 2025
Type: article
Source: Journal of Clinical Oncology
Authors: Megan Crumbaker, Laurence Krieger, David William Pook, Ian D. Davis, Antoinette Fontela, Christopher Oldmeadow, Josh Hurwitz, Andrisha Jade Inderjeeth, Haryana M. Dhillon, Teesha Downton, Gavin M. Marx, Samantha Shekar, Emmanuel S. Antonarakis, Samuel R. Denmeade, Angelyn Anton, Thean Hsiang Tan, Sharad Sharma, Jeffrey C. Goh, Lisa Horvath, Anthony M. Joshua, The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Institutions: St Vincent's Hospital Sydney, The Kinghorn Cancer Centre, Royal North Shore Hospital, GenesisCare, Monash Medical Centre, Eastern Health, Monash University, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Hunter Medical Research Institute, South Metropolitan Health Service, The University of Sydney, Sydney Adventist Hospital, University of Minnesota, Masonic Cancer Center, Johns Hopkins University, Royal Adelaide Hospital, Ballarat Health Services, Royal Brisbane and Women's Hospital, Chris O’Brien Lifehouse
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Cancer Australia
OpenAlex ID: W4407699794